Ads
related to: rituximab mech of action 1 24
Search results
Results From The WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
3.1 Mechanism of action. ... 400 mg once daily for 24 months measured from the rituximab ... on days 1 and 2 of each 28-day cycle and rituximab at the above described ...
Rituximab: 375 mg/m 2: IV infusion: Day 1 Etoposide: 50 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 Hydroxydaunorubicin ...
Idelalisib is a second-line medication for people whose chronic lymphocytic leukemia (CLL) has relapsed. Used in combination with rituximab, [9] idelalisib is to be used in people for whom rituximab alone would be considered appropriate therapy due to other existing medical conditions. [9]
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. [6] [4]The most common side effects include neutropenia (low levels of neutrophils, a type of white blood cell), infusion reactions, pneumonia (infection of the lungs), upper respiratory tract infection (such as nose and throat infections), diarrhoea and bronchitis ...
Complement-dependent cytotoxicity (CDC) is an effector function of IgG and IgM antibodies.When they are bound to surface antigen on target cell (e.g. bacterial or viral infected cell), the classical complement pathway is triggered by bonding protein C1q to these antibodies, resulting in formation of a membrane attack complex (MAC) and target cell lysis.
Infrequent adverse effects (0.1–1% of people) include esophagitis, gastritis, gastrointestinal tract hemorrhage, and/or invasive cytomegalovirus (CMV) infection. [19] More rarely, pulmonary fibrosis or various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with ...